- Home
- GYRE
as 05-29-2025 4:00pm EST
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 897.1M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 328.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.11 - $19.00 | Next Earning Date: | 05-09-2025 |
| Revenue: | $100,643,000 | Revenue Growth: | -13.01% |
| Revenue Growth (this year): | 22.01% | Revenue Growth (next year): | 88.14% |
Stock Insider Trading Activity of Gyre Therapeutics Inc. (GYRE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ma Songjiang | GYRE | President | May 22 '25 | Sell | $10.61 | 2,182 | $23,803.68 | 2,808,642 | |
| Ma Songjiang | GYRE | President | May 20 '25 | Sell | $11.04 | 4,000 | $44,160.00 | 2,808,642 | |
| Ma Songjiang | GYRE | President | May 16 '25 | Sell | $11.21 | 4,000 | $44,840.00 | 2,808,642 | |
| Ma Songjiang | GYRE | President | May 14 '25 | Sell | $10.99 | 2,020 | $21,586.00 | 2,808,642 | |
| Ma Songjiang | GYRE | President | May 12 '25 | Sell | $10.97 | 4,000 | $43,860.00 | 2,808,642 | |
| Ma Songjiang | GYRE | President | Mar 21 '25 | Sell | $10.00 | 174 | $1,740.00 | 2,808,642 | |
| Ma Songjiang | GYRE | President | Mar 19 '25 | Sell | $10.11 | 4,000 | $40,440.00 | 2,808,642 | |
| Ma Songjiang | GYRE | President | Mar 17 '25 | Sell | $11.17 | 2,242 | $26,658.08 | 2,808,642 | |
| Ma Songjiang | GYRE | President | Mar 13 '25 | Sell | $12.06 | 4,000 | $48,220.00 | 2,808,642 | |
| Ma Songjiang | GYRE | President | Mar 11 '25 | Sell | $11.57 | 4,000 | $46,280.00 | 2,808,642 |
Latest Gyre Therapeutics Inc. News
GYRE Breaking Stock News: Dive into GYRE Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
GlobeNewswire
7 days ago
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
GlobeNewswire
7 days ago
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
Simply Wall St.
20 days ago
Gyre Therapeutics First Quarter 2025 Earnings: EPS: US$0.031 (vs US$0.09 in 1Q 2024)
GlobeNewswire
21 days ago
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Simply Wall St.
23 days ago
A Note On Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE and Debt To Equity
GlobeNewswire
2 months ago
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
Simply Wall St.
2 months ago
We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings
Compare GYRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GYRE Gyre Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.